男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Europe

Hope for HIV patients as drug from GSK goes to human trials

By ANGUS McNEICE in London | China Daily Global | Updated: 2021-12-02 10:39
Share
Share - WeChat
The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, on March 21, 2018. [Photo/Agencies]

A human trial into a potential cure for HIV will commence in 2022, United Kingdom pharmaceutical company GSK has announced, after the treatment gained encouraging results from animal testing.

A GSK executive made the announcement in the lead-up to World AIDS Day, which is an international public health campaign established by the World Health Organization and the United Nations that falls on Dec.1 each year.

Kimberly Smith, head of research and development at GSK's HIV arm ViiV Healthcare, said during an investor meeting on Monday that the company plans on testing one of its most promising HIV treatments on humans by summer next year.

Antiviral therapies already exist that can suppress HIV to the point where the virus is undetectable in infected people. But totally eliminating the disease in patients has proved to be a monumental medical challenge, since the virus can lay dormant within cells in the body.

Smith said that the drug from ViiV is capable of "waking up" these dormant viral reservoirs, exposing them to attack from the other therapies and the immune system. Smith said that the drug has been through successful trials in animals including non-human primates.

"The idea is that you have to wake up the latent virus and try to get rid of it," Smith told the Daily Telegraph ahead of the investor meeting. "If it works in humans, then the question will be how do we clear it away once we've induced it."

Smith also said she believes finding a cure for HIV is achievable this decade. Around 38 million people across the world live with the disease, according to the UN.

"Our ultimate goal is always a cure of HIV," Smith told investors. "I hope that we'll contribute to getting there by 2030, if not sooner."

GSK has been at the forefront of HIV drug research since the 1980s, when researchers at company predecessor Burroughs Wellcome first conceived of using the drug azidothymidine, or AZT, as a treatment for the disease.

The company established ViiV to manage its HIV business in 2009, along with two minority shareholders, United States-based Pfizer and Japan-based Shionogi. ViiV has 16 drugs in its HIV portfolio that generated around $6.5 billion in sales last year, according to the company.

But GSK as a whole has struggled in recent years, with an underperforming drug pipeline, investor rumblings over strategy and leadership, and the emergence of a serious rival in AstraZeneca, which has developed one of the most widely-used COVID-19 vaccines.

GSK is also set to lose exclusivity on one of its HIV drug patents in eight years' time, and Smith attempted to quell investor concerns by setting out the company's long-term HIV strategy at the meeting.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 志丹县| 东明县| 萨嘎县| 鱼台县| 武城县| 楚雄市| 武功县| 台中市| 鄱阳县| 定结县| 墨玉县| 海伦市| 乐山市| 陇川县| 含山县| 五莲县| 江陵县| 富民县| 合作市| 阿图什市| 湟中县| 甘德县| 吉木萨尔县| 穆棱市| 象山县| 镇远县| 保靖县| 宜都市| 军事| 惠安县| 象州县| 原阳县| 翁牛特旗| 内丘县| 丹巴县| 峡江县| 汤原县| 合川市| 来凤县| 满洲里市| 隆昌县|